

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

212849Orig1s000

Trade Name: RYKINDO

Generic or Proper Name: Risperidone

Sponsor: Shandong Luye Pharmaceutical Co., Ltd

Approval Date: January 13, 2023

Indication: RYKINDO (risperidone) for extended-release injectable suspension, for intramuscular use, is indicated for treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder in adults.

CENTER FOR DRUG EVALUATION AND RESEARCH

212849Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) • Summary Review • Clinical • Non-Clinical • Statistical • Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

212849Orig1s000

APPROVAL LETTER



NDA 212849

NDA APPROVAL

Shandong Luye Pharmaceutical Co., Ltd.
c/o Luye Pharma (USA) Ltd.
Attention: Hongtao Zhang, MS, MBA
Senior Director, Clinical Regulatory Affairs
502 Carnegie Center, Suite 100
Princeton, NJ 08540

Dear Mr. Zhang:

Please refer to your new drug application (NDA) dated and received March 28, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Rykindo (risperidone) for extended-release injectable suspension, for intramuscular use.

We acknowledge receipt of your amendments dated August 19, 2021, and July 14, 2022, which constituted a complete response to our January 28, 2020, action letter.

This NDA provides for the use of Rykindo (risperidone) for extended-release injectable suspension, for intramuscular use, for treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder in adults.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 212849.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Rykindo (risperidone) for extended-release injectable suspension, for intramuscular use, shall be 24 months from the date of manufacture when stored at 2° to 8°C. The expiry dating period for the diluent vial shall be 36 months from the date of manufacture when stored at 2° to 8°C. The expiration date for the packaged product, Rykindo plus diluent, shall be dependent on the shortest expiration date of any component.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA; 21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because, given the low numbers of pediatric patients with schizophrenia or bipolar I disorder treated with risperdone long-acting injection, it would be impracticable to conduct meaningful clinical trials in the pediatric population.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Tiffanie Taylor, Regulatory Project Manager, at Tiffanie.Taylor@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Bernard Fischer, MD
Deputy Director
Division of Psychiatry
Office of Neuroscience
Center for Drug Evaluation and Research

³ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BERNARD A FISCHER
01/13/2023 05:25:45 PM